Patent Grant
8790707
Publication No. US 2008/0187500 (abstract) describes a solid-state method of producing functionalized moieties, including placing predetermined amounts of inorganic and organic materials and milling media into a vessel rotatably connected to a turntable platform, rotating the vessel in a first direction while turning the turntable platform in a second direction counter to the first direction, milling the inorganic and organic materials into smaller respective organic and inorganic particles, and fusing portions of organic particles to inorganic parties to define functionalized moieties. The inorganic material may include calcium phosphates of varying phases, structure, and composition. The organic material may include anionic surfactants, cationic surfactants, neutral surfactants, carboxylic acids, polymers, copolymers, block copolymers, and combinations thereof.
In one embodiment, tricalcium phosphate particles are described comprising a surface treatment wherein the surface treatment comprises at least one sugar alcohol, at least one glycerophosphoric acid compound, or mixture thereof.
In another embodiment, calcium phosphate particles are described comprising a surface treatment wherein the surface treatment comprises at least one sugar alcohol. The surface treated calcium phosphate particles can provide calcium and phosphorous to the (e.g. oral) environment for remineralization by neighboring teeth and bone.
In other embodiments, various oral care compositions are described comprising calcium phosphate particles surface treated with at least one sugar alcohol, at least one glycerophosphoric acid compound, or mixture thereof. Such oral care compositions preferably further comprise a fluoride-providing agent. The surface treated calcium phosphate particles are amenable to increasing the concentration of bioavailable fluoride.
In another embodiment, a method of surface treating calcium phosphate particles is also described. The method comprises dissolving at least one sugar alcohol into a liquid medium to provide a surface treatment solution; dispersing calcium phosphate particles in the surface treatment solution; and removing the liquid medium to obtain dried surface treated calcium phosphate particles.
Presently described are calcium phosphate particles, such as tricalcium phosphate particles, comprising a surface treatment. The surface treatment comprises at least one sugar alcohol and/or at least one glycerophosphoric acid compound.
The surface treated calcium phosphate particles are particularly useful for oral care compositions and methods for administration or application to, or use with, a human or other animal subject. As referred to herein, an “oral care composition” is any composition that is suitable for administration or application to the oral cavity of a human or animal subject for enhancing the health, hygiene or appearance of the subject, preferably providing such benefits as: the prevention or treatment of a condition or disorder of the teeth, gums, mucosa or other hard or soft tissue of the oral cavity; the prevention or treatment of a systemic condition or disorder; the provision of sensory, decorative, or cosmetic benefits; and combinations thereof. Typically, an oral care composition is not intentionally swallowed, but is rather retained in the oral cavity for a time sufficient to provide the intended utility. Alternatively, in some embodiments, such as when the oral care composition is for example a lozenge, soluble film, or dental varnish, the oral care composition may be ingested. Oral care compositions include, for example, dentifrices, gels, crèmes, rinses, prophylactic pastes, foams, sprays, adherent strips and patches, gels, enamel conditioning materials, desensitizers, orally soluble films, tablets, chewing gums, lozenges, powders, granules, dental coatings, and dental varnishes.
Alternatively, the surface treated calcium phosphate particles can be employed in a hardenable dental composition, dental article, or orthodontic appliance.
As used herein, “dental composition” refers to an unfilled or filled (e.g. a composite) material (e.g., a dental or orthodontic material) capable of adhering (e.g., bonding) to an oral surface. Dental compositions include, for example, adhesives (e.g., dental and/or orthodontic adhesives), cements (e.g., glass ionomer cements, resin-modified glass ionomer cements, and/or orthodontic cements), primers (e.g., orthodontic primers), restoratives such as dental fillings, liners, sealants (e.g., orthodontic sealants), and coatings. Oftentimes a dental composition can be used to bond a dental article to a tooth structure.
As used herein, “dental article” refers to an article that can be adhered (e.g., bonded) to a tooth structure. Dental articles include, for example, crowns, bridges. veneers, inlays, onlays, fillings, implants, orthodontic appliances and devices, and prostheses (e.g., partial or full dentures).
As used herein, “orthodontic appliance” refers to any device intended to be bonded to a tooth structure, including, but not limited to, orthodontic brackets, buccal tubes, lingual retainers, orthodontic bands, bite openers, buttons, and cleats. The appliance has a base for receiving adhesive and it can be a flange made of metal, plastic, ceramic, or combinations thereof. Alternatively, the base can be a custom base formed from cured adhesive layer(s) (i.e., single or multi-layer adhesives).
As used herein, an “oral surface” refers to a soft or hard surface in the oral environment. Hard surfaces typically include tooth structure including, for example, natural and artificial tooth surfaces, bone, tooth models, and the like.
As used herein, “hardenable” is descriptive of a material or composition that can be cured (e.g., polymerized or crosslinked) or solidified, for example, by removing solvent (e.g., by evaporation and/or heating); heating to induce polymerization and/or crosslinking; irradiating to induce polymerization and/or crosslinking; and/or by mixing one or more components to induce polymerization and/or crosslinking. “Mixing” can be performed, for example, by combining two or more parts and mixing to form a homogeneous composition. Alternatively, two or more parts can be provided as separate layers that intermix (e.g., spontaneously or upon application of shear stress) at the interface to initiate polymerization.
As used herein, “hardened” refers to a material or composition that has been cured (e.g., polymerized or crosslinked) or solidified.
Calcium phosphates are inorganic compounds constituted by Ca2+ and phosphate ions at different stoichiometric amounts that contain at least one Ca—O—P linkage. Phosphate ions are pentavalent phosphorus compounds that contain at least one phosphorus-oxygen bond. For example, the phosphate ions can be PO43−, pyrophosphate (P2O74−), polyphosphate (ring and chain polyphosphates), substituted phosphates like fluorophosphates (for example, PO3F2−, PO2F2−) and other halophosphates, thiophosphates, and amidophosphates. The calcium phosphate structure can comprise up to 50 wt-% of other ions. For example, a portion of the Ca2+ ions can be replaced with Na+, K+, Mg2+, and mixtures thereof. Further, the oxygen atoms of the PO43− ion can be replaced with F−, CO32−, OH−, and mixtures thereof. Typically, no greater than about 20 wt-% of other ions are present in the calcium phosphate structure. In some embodiments, the percentage of other ions in the calcium phosphate structure is no greater than 15, 10, 5, or 1 wt-%.
Suitable calcium phosphates may be any of the various crystalline or amorphous forms. Suitable calcium phosphates include tricalcium phosphate (TCP), monocalcium phosphate (MCP), dicalcium phosphate (DCP), calcium monofluorophosphate, calcium pyrophosphate (CPP), octocalcium phosphate (OCP), amorphous calcium phosphate (ACP), hydroxyapatite (HAP), fluoroapatite (FAP), tetracalcium phosphate (TTCP). Many of these have anhydrous and one or more hydrated forms. Also included are calcium phosphate materials doped with other cations or anions, e.g. Sr, Ba, Mg, Zn; Na, K, rare earths; OH, F, and carbonate. In some embodiments, the calcium phosphate is preferably tricalcium phosphate (TCP).
The calcium phosphate particles may have any finely divided form. The particles may have a wide variety of shapes, including equiaxed, spherical, oblate, discs, whiskers, fibers, platelets, etc. Generally the particle size is no greater than about 100 micrometers, and preferably no greater than about 75, 50, 25, 15, 10, 5, or even less than about 1 micron. The calcium phosphate particles may be nanoparticles, having a particle size less than 1 micron. The calcium phosphate nanoparticles may have a particle size of no greater than 500 nm, 200 nm, 150 nm, 100 nm, or even 50 nm. The particles may have a wide variety of shapes, including equiaxed, spherical, oblate, discs, whiskers, fibers, platelets, etc.
In some embodiments, the calcium phosphate particles are ground and optionally classified such that the particles are relatively monodisperse. In other embodiments, the particle may have a wide particle size distribution. For example, the largest particles may be approximately 5 to 100 times the size of the smallest particles.
The calcium phosphate particles are surface treated. There are a variety of methods for surface treating the particles. In some embodiments, the calcium phosphate particles are surface treated by means of a solution process. Solution processes typically involve dissolving or dispersing the surface treatment into a liquid (e.g. aqueous) medium; dispersing the calcium phosphate particles in the surface treatment solution; and removing the liquid to obtain dry powder. Drying may be accomplished by various means including oven drying, gap drying, spray drying, or lyophilization. Optionally, instead of drying, another liquid may be exchanged for the initial liquid medium; for example, when the liquid medium is volatile (e.g. water, ethanol), a non-volatile liquid (e.g. glycerol, methacrylate resin) may be blended into the dispersion, and then the initial liquid medium evaporated away leaving the treated particles in the new liquid, e.g. via rotary evaporation. The solution process may be aqueous, sparingly aqueous, or anhydrous. Other method of surface treating the calcium phosphate particles include milling processes, that involve comminuting or physically blending the treatment with the particulates in a mill, e.g. V-shell blender, ball mill, attritor mill, etc.; milling may be done dry or wet.
The concentration of surface treatment on the calcium phosphate particles is typically at least 0.05% by weight; in some embodiments, the concentration of surface treatment is at least 0.1, 0.2, 0.5, 1, 2, or even at least 2% by weight. The concentration of surface treatment on the calcium phosphate particles is typically no greater than about 20% by weight; in some embodiments, the concentration is no greater than about 15, 10, or even 5% by weight. In some embodiments, the concentration of surface treatment on the calcium phosphate particles ranges from about 0.1 wt-% to 10 wt-%.
In some embodiments, the surface treatment comprises at least one sugar alcohol. A sugar alcohol (also known as a polyol, polyhydric alcohol, or polyalcohol) is a hydrogenated form of carbohydrate wherein its carbonyl group (aldehyde or ketone) has been reduced to a primary or secondary alcohol. Common sugar alcohols have the general formula:
HOCH2[CH(OH)]nCH2OH
wherein n ranges from 4 to 6. In some embodiments, the sugar alcohol is preferably xylitol (n=5). In other embodiments, the sugar alcohol is erythritol (n=4) or sorbitol (n=6).
In other embodiments, the surface treatment comprises a glycerophosphoric acid compound. As used herein, glycerophosphoric acid compound refers toglycerophosphoric acid as ell as salts and hydrates thereof. The glycerophosphoric acid compounds have the general formula:
(HO)2C3H6(O)P(O)(O−)2(M+n)2/n
wherein M is H, or a metal ion having a valency of n.
Glycerophosphoric acid (also referred to as phosphoric acid glycerol ester exists as three isomers, beta-glycerophosphoric acid and the D(+) and L(−) forms of alpha-glycerophosphoric acid. Commercially available glycerophosphoric acid is typically a mixture of the alpha- and beta-glycerophosphoric acids.
Glycerophosphate salts may further comprise one or more waters of hydration. In preferred embodiments, the glycerophosphoric acid compound is sodium glycerophosphate, calcium glycerophosphate (CGP), or glycerophosphoric acid.
The oral care compositions described herein typically comprise an effective amount of surface treated calcium phosphate particles to enhance the natural remineralizing. The hardenable dental compositions also enhance natural remineralization, but typically at a much slower rate relative to the oral care compositions. Although the effective amount can vary, the oral care composition typically comprises at least about 0.01% calcium phosphate particles; in some embodiments, the composition may comprise at least about 0.02, 0.05, 0.08, 0.1, 0.5, 1, 2, 5, or even 8% calcium phosphate particles. The amount of calcium phosphate particles is typically no greater than 99%; in some embodiments, the amount of calcium phosphate particles is no greater than 90, 80, 70, 60, 50, or even 40%. A preferred range of calcium phosphate particles is 0.02% to 40%.
In preferred embodiments, the oral care compositions further comprise a fluoride-providing agent that is a source of fluoride-ion. Fluoride-providing agents are well known as anti-caries agents. The fluoride-providing agents are sufficiently water soluble to release an anti-carious amount of fluoride ions in water or the saliva. Suitable fluoride-providing agents are organic or inorganic.
With reference to
Inorganic fluoride ion-providing agents include metal, alkali metal, alkaline earth metal and ammonium salts of fluoride, such as for example potassium fluoride, sodium fluoride, ammonium bifluoride, calcium fluoride, a copper fluoride such as cuprous fluoride, barium fluoride, sodium fluorosilicate, ammonium fluorosilicate, sodium fluorozirconate, sodium monofluorophosphate, aluminum mono- and di-fluorophosphate, fluorinated sodium calcium pyrophosphate, stannous fluoride, lithium fluoride, cesium fluoride, aluminum fluoride, cupric fluoride, indium fluoride, stannous fluorozirconate, ferric fluoride, nickel fluoride, palladium fluoride, silver fluoride, zirconium fluoride, and mixtures thereof. Another class of fluoride sources is fluoride-containing glasses, such as fluoroaluminosilicate glasses. Suitable fluoroaluminosilicate glasses are described in U.S. Pat. No. 5,063,257, U.S. Pat. No. 4,209,434, and U.S. Pat. No. 4,043,327. Preferred inorganic fluoride ion-providing agents are sodium monofluorophosphate, stannous fluoride, sodium fluoride, and fluoroaluminosilicate glass.
Organic fluoride ion-providing agents include hexylamine hydrofluoride, laurylamine hydrofluoride, myristylamine hydrofluoride, decanolamine hydrofluoride, octadecenylamine hydrofluoride, myristoxyamine hydrofluoride, diethylaminoethyloctoylamide hydrofluoride, diethanolamineoethyloleylamide hydrofluoride, diethanolaminopropyl-N′-octadecenylamine dihydrofluoride, 1-ethanol-2-hexadecylimidazoline dihydrofluoride, octoylethanolamine hydrofluoride, octyltrimethylammonium fluoride, dodecylethyldimethylammonium fluoride, tetraethylammonium fluoride, dilauryldimethylammonium fluoride, .delta.8-9 octadecenylbenzyldimethylammonium fluoride, dioctyldiethylammonium fluoride, cyclohexylcetyldimethylammonium fluoride, furfuryllauryidimethylammonium fluoride, phenoxyethylcetyldimethylammonium fluoride, N:N′-tetramethyl-N:N′-dilaurylethylenediammonium difluoride, N-cetylpyridinium fluoride, N:N-dilauryl-morpholinium fluoride, N-myristyl-N-ethylmorpholinium fluoride, N-(octylaminocarbonylethyl)-N-benzyldimethylammonium fluoride, N—(B-hydroxydodecyl)trimethylammonium fluoride, N-phenyl-N-hexadecyldiethylammonium fluoride, N-cyclohexyl-N-octadecyldimethylammonium fluoride, N-(2-carbomethoxyethyl)-N-benzyldimethylammonium fluoride, N-(2-carbocyclohexoxyethyl)-N-myristyldimethylammonium fluoride, N-(2-carbobenzyloxyethyl)-N-dodecyldimethylammonium fluoride, N-[2-(N:N′-dimethylaminocarbonyl)-ethyl]-N-dodecyidiethylammonium fluoride, N-carboxymethyl-N-cicosyldimethylammonium fluoride, olaflur (N′-octadecyltrimethylendiamine-N,N,N′-tris(2-ethanol)-dihydrofluoride), betaine hydrofluoride, sarcosine stannous fluoride, alanine stannous fluoride, glycine potassium fluoride, sarcosine potassium fluoride, glycine hydrofluoride, tetrapropylammonium tetrafluoroborate, tetrabutylammonium tetrafluoroborate, benzyltriethylammonium tetrafluoroborate, lysine hydrofluoride, alanine hydrofluoride, betaine zirconium fluoride, and mixtures thereof. Preferred organic fluoride sources include tetrapropylammonium tetrafluoroborate, tetrabutylammonium tetrafluoroborate, and benzyltriethylammonium tetrafluoroborate.
The fluoride-providing agent is present in an amount sufficient to release between about 200 ppm to 6000 ppm fluoride ion, preferably from about 800 to about 1500 ppm fluoride ion. The fluoride-providing agent may be present in the composition from about 0.001% to about 5% by weight.
The surface treated calcium phosphate particles, optionally in combination with the fluoride-providing agent, may be provided in an “orally acceptable carrier”. Preferably, the carrier does not substantially reduce the efficacy of the active materials of the present compositions. Selection of specific carrier components is dependent on the desired product form, including dentifrices, rinses, gels, paints, toothpastes, tooth powders, prophylaxis pastes, as well as confectionary compositions such as lozenges, gums, and dissolvable films.
In various embodiments, the orally acceptable carrier used to prepare the oral care composition is aqueous. As recognized by one of skill in the art, the oral care compositions of the present invention optionally include other materials, such as for example, anticaries agents, including the fluoride providing agents already described, desensitizing agents, viscosity modifiers, diluents, surface active agents, such as surfactants, emulsifiers, and foam modulators, pH modifying agents, abrasives, humectants, mouth-feel agents, sweetening agents, flavor agents, colorants, preservatives, and combinations thereof.
When the surface treatment comprises a sugar alcohol, the concentration of sugar alcohol may be sufficient to concurrently sweeten the oral care composition. However, additional sugar alcohols or other sweeteners can be added as desired. Such sweeteners include dextrose, polydextrose, sucrose, maltose, dextrin, dried invert sugar, mannose, xylose, ribose, fructose, levulose, galactose, corn syrup (including high fructose corn syrup and corn syrup solids), partially hydrolyzed starch, hydrogenated starch hydrolysate, sorbitol, mannitol, xylitol, maltitol, isomalt, aspartame, neotame, saccharin and salts thereof, sucralose, dipeptide-based intense sweeteners, cyclamates, dihydrochalcones, and mixtures thereof. One or more sweeteners are optionally present in a total amount depending strongly on the particular sweetener(s) selected, but typically at levels of from about 0.005% to about 5% by weight, optionally from about 0.01% to about 1% by weight.
In preferred embodiments, the oral care composition may be a dentifrice. As referred to herein, a “dentifrice” is a composition that is intended for cleaning a hard surface within the oral cavity. Such dentifrices include toothpowder, a dental tablet, toothpaste (dental cream), or gel. In a toothpaste dentifrice, the orally acceptable vehicle may comprise water and humectant each typically in an amount ranging from about 10% to about 80% by weight of the oral care composition.
Humectants useful herein include polyhydric alcohols such as glycerin, sorbitol, xylitol and low molecular weight polyethylene glycols, including those listed above herein. In various embodiments, humectants are operable to prevent hardening of paste or gel compositions upon exposure to air. In various embodiments humectants also function as sweeteners. One or more humectants are optionally present in a total amount of about 1% to about 70% by weight, for example about 2% to about 25% by weight or about 5% to about 15% by weight.
In various embodiments, toothpastes, creams and gels contain a natural or synthetic thickener or gelling agent, which, other than silica thickeners, include natural and synthetic gums and colloids. In a still further embodiment a composition of the invention comprises at least one thickening agent, useful for example to impart a desired consistency and/or mouth feel to the composition. Any orally acceptable thickening agent can be used, including without limitation carbomers, also known as carboxyvinyl polymers, carrageenans, also known as Irish moss and more particularly-carrageenan (iota-carrageenan), cellulosic polymers such as hydroxyethylcellulose, carboxymethylcellulose (CMC) and salts thereof, e.g., CMC sodium, natural gums such as karaya, xanthan, gum arabic and tragacanth, colloidal magnesium aluminum silicate, colloidal silica and the like. One or more thickening agents are optionally present in a total amount of about 0.01% to about 15%, for example about 0.1% to about 10% or about 0.2% to about 5% by weight of the composition.
In some embodiments, the oral composition comprises substances capable of forming an adherent film or coating on the tooth or soft tissue. The duration of the coating may be minutes, hours, days, weeks, or months. Preferably, the film-forming substance is dissolved or dispersed in a liquid carrier. Preferred film-forming substances include rosins, esterified rosins, and polymeric film formers as described in provisional patent application Ser. No. 61/013,464; incorporated herein by reference. Some suitable rosins and esterified rosins are described in U.S. Pat. No. 7,335,691, US 2007/0105975, and U.S. Pat. No. 4,396,378.
In various embodiments of the present invention, where the vehicle of the oral care composition is solid or a paste, the oral care composition may comprise a dentally acceptable abrasive material or polishing agent, which may serve to either polish the tooth enamel or provide a whitening effect. Any orally acceptable abrasive can be used, but type, fineness (particle size) and amount of abrasive should be selected so that tooth enamel and dentin are not excessively abraded in normal use of the composition. Suitable abrasives include without limitation silica, for example in the form of silica gel, hydrated silica or precipitated silica, alumina, insoluble phosphates, calcium carbonate, resinous abrasives such as urea-formaldehyde condensation products and the like. Suitable abrasive particles for oral care compositions are available from J. M Huber under the tradename ZEODENT; Grace Davison under SYLODENT; Degussa under SIDENT. Among phosphates useful as abrasives are orthophosphates, polymetaphosphates and pyrophosphates. Illustrative examples are dicalcium orthophosphate dihydrate, calcium pyrophosphate, beta-calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate and insoluble sodium polymetaphosphate. Hence, in some embodiments, the surface treated calcium phosphate particles can serve as an abrasive concurrent with providing a source of calcium and phosphate ions. One or more abrasives are optionally present in an abrasive effective total amount, typically about 4% to about 70%, for example about 8% to about 50%, or about 10% to about 30% by weight of the composition. Average particle size of an abrasive, if present, is generally about 0.1 to about 50 μm, for example about 1 to about 40 μm or about 5 to about 30 μm.
The oral care compositions can be used in a method to treat or prevent dental caries in a human or animal subject comprising administering a safe and effective amount of an oral care composition to the oral cavity of the subject. As used herein “animal subject” includes higher order non-human mammals such as equines, canines, and felines. The oral care composition is contacted with an oral surface of the mammalian subject to thereby provide calcium and phosphate ions to promote remineralization and prevent demineralization.
The calcium phosphate particles may also be employed in a variety of hardenable dental compositions, dental articles, and orthodontic appliances, as previously described. For example, the surface treated calcium phosphate particles can be incorporated into a variety of dental and orthodontic compositions including dental varnishes and coatings; enamel lesion treatment; surface or margin-sealing gloss; adhesives and primers; desensitizing agent; dentifrice; prophy paste; restoratives; root canal filling, sealer, or primer; cements (temporary and permanent); mill blocks; gel/mousse/foam; liner/base; root and cavity desensitizing agent; pit/fissure sealant; orthodontic adhesives, cements, primers; sprays; tooth-adherent patches and strips.
The hardenable component of the dental composition can include a wide variety of chemistries, such as ethylenically unsaturated compounds (with or without acid functionality), epoxy (oxirane) resins, vinyl ethers, (e.g. photopolymerization) initiator systems, redox cure systems, glass ionomer cements, polyethers, polysiloxanes, and the like.
In certain embodiments, the compositions are photopolymerizable, i.e., the compositions contain a photoinitiator (i.e., a photoinitiator system) that upon irradiation with actinic radiation initiates the polymerization (or hardening) of the composition. Such photopolymerizable compositions can be free radically polymerizable or cationically polymerizable. In other embodiments, the compositions are chemically hardenable, i.e., the compositions contain a chemical initiator (i.e., initiator system) that can polymerize, cure, or otherwise harden the composition without dependence on irradiation with actinic radiation. Such chemically hardenable compositions are sometimes referred to as “self-cure” compositions and may include glass ionomer cements (e.g., conventional and resin-modified glass ionomer cements), redox cure systems, and combinations thereof.
Suitable photopolymerizable components that can be used in the dental compositions of the present invention include, for example, epoxy resins (which contain cationically active epoxy groups), vinyl ether resins (which contain cationically active vinyl ether groups), ethylenically unsaturated compounds (which contain free radically active unsaturated groups, e.g., acrylates and methacrylates), and combinations thereof. Also suitable are polymerizable materials that contain both a cationically active functional group and a free radically active functional group in a single compound. Examples include epoxy-functional acrylates, epoxy-functional methacrylates, and combinations thereof.
The (e.g., photopolymerizable) dental compositions may include compounds having free radically active functional groups that may include monomers, oligomers, and polymers having one or more ethylenically unsaturated group. Suitable compounds contain at least one ethylenically unsaturated bond and are capable of undergoing addition polymerization. Examples of useful ethylenically unsaturated compounds include acrylic acid esters, methacrylic acid esters, hydroxy-functional acrylic acid esters, hydroxy-functional methacrylic acid esters, and combinations thereof. Such free radically polymerizable compounds include mono-, di- or poly-(meth)acrylates (i.e., acrylates and methacrylates) such as, methyl (meth)acrylate, ethyl (meth)acrylate, isopropyl (meth)acrylate, n-hexyl (meth)acrylate, stearyl (meth)acrylate, allyl (meth)acrylate, glycerol tri(meth)acrylate, ethyleneglycol di(meth)acrylate, diethyleneglycol di(meth)acrylate, triethyleneglycol di(meth)acrylate, 1,3-propanediol di(meth)acrylate, trimethylolpropane tri(meth)acrylate, 1,2,4-butanetriol tri(meth)acrylate, 1,4-cyclohexanediol di(meth)acrylate, pentaerythritol tetra(meth)acrylate, sorbitol hex(meth)acrylate, tetrahydrofurfuryl (meth)acrylate, bis[1-(2-acryloxy)]-p-ethoxyphenyldimethylmethane, bis[1-(3-acryloxy-2-hydroxy)]-p-propoxyphenyldimethylmethane, ethoxylated bisphenolA di(meth)acrylate, and trishydroxyethyl-isocyanurate tri(meth)acrylate; (meth)acrylamides (i.e., acrylamides and methacrylamides) such as (meth)acrylamide, methylene bis-(meth)acrylamide, and diacetone (meth)acrylamide; urethane (meth)acrylates; the bis-(meth)acrylates of polyethylene glycols (preferably of molecular weight 200-500), copolymerizable mixtures of acrylated monomers such as those in U.S. Pat. No. 4,652,274 (Boettcher et al.), acrylated oligomers such as those of U.S. Pat. No. 4,642,126 (Zador et al.), and poly(ethylenically unsaturated) carbamoyl isocyanurates such as those disclosed in U.S. Pat. No. 4,648,843 (Mitra); and vinyl compounds such as styrene, diallyl phthalate, divinyl succinate, divinyl adipate and divinyl phthalate. Other suitable free radically polymerizable compounds include siloxane-functional (meth)acrylates as disclosed, for example, in PCT International Publication Nos. WO 00/38619 (Guggenberger et al.), WO 01/92271 (Weinmann et al.), WO 01/07444 (Guggenberger et al.), and WO 00/42092 (Guggenberger et al.); and fluoropolymer-functional (meth)acrylates as disclosed, for example, in U.S. Pat. No. 5,076,844 (Fock et al.) and U.S. Pat. No. 4,356,296 (Griffith et al.) and European Pat. Application Publication Nos. EP 0373 384 (Wagenknecht et al.), EP 0201 031 (Reiners et al.), and EP 0201 778 (Reiners et al.). Mixtures of two or more free radically polymerizable compounds can be used if desired.
The hardenable dental composition may also contain hydroxyl groups and ethylenically unsaturated groups in a single molecule. Examples of such materials include hydroxyalkyl (meth)acrylates, such as 2-hydroxyethyl (meth)acrylate and 2-hydroxypropyl (meth)acrylate; glycerol mono- or di-(meth)acrylate; trimethylolpropane mono- or di-(meth)acrylate; pentaerythritol mono-, di-, and tri-(meth)acrylate; sorbitol mono-, di-, tri-, tetra-, or penta-(meth)acrylate; and 2,2-bis[4-(2-hydroxy-3-ethacryloxypropoxy)phenyl]propane (bisGMA). Suitable ethylenically unsaturated compounds are also available from a wide variety of commercial sources, such as Sigma-Aldrich, St. Louis. Mixtures of ethylenically unsaturated compounds can be used if desired.
31.9 g of TCP was blended with 1.3 g of a 60% aqueous solution of xylitol and 36.1 g of deionized water (DIW) to form a thin slurry; stirred for 1 hr; dried at 80 C for 18 hr. The resulting soft cake crushed readily to yield fine powder, and was calculated to have 2% xylitol treatment on the TCP powder.
33.6 g of TCP was blended with 2.2 g of a 34.1% aqueous solution of NGP and 52.9 g of DIW to form a thin slurry; stirred for 1 hr; dried at 80 C for 18 hr. The resulting soft cake crushed readily to yield fine powder, and was calculated to have 2% NGP treatment on the TCP powder.
Two dentifrice formulations were compounded by mixing 0.5% of the surface treated TCP with 99.5% of a toothpaste commercially available from 3M ESPE, under the trade designation “Omni ControlRx Prescription Fluoride Toothpaste”. The ingredients listed on the product label include 1.1% neutral sodium fluoride (5000 ppm F)(w/w), MICRODENT™, deionized water, sorbitol, hydrated silica, glycerin, PEG-12, cellulose gum, sodium lauryl sulfate, flavor, titanium dioxide, and sodium saccharin.
2 g of the paste or solution are injected via syringe into 40 g of a 1:1 solution of Total Ionic Strength Adjustment Buffer (Thermo Orion, Beverly, Mass.) and deionoized water (paste:solution=1:20). Fluoride is measured via a fluoride-selective electrode before adding paste (t=0); then 30 sec; 1 min; and each minute after for 10 min total.
Data collected for modified ControlRx formulations are shown in
3M™ ESPE™ Vitrebond™ Plus Light Cure Glass Ionomer Liner/Base
3M™ ESPE™ Clinpro™ Sealant
Omni™ Vanish™ 5% Sodium Fluoride White Varnish (3M™ ESPE™)
The compositions in the table were mixed into smooth, creamy pastes. The following evaluations were conducted:
A small, pea-sized amount of each paste was mixed with an equivalent volume of the clear liquid component of Vitrebond Plus liner/base. The mixing and handling was the same as that of Vitrebond Plus liner/base. A portion of the mixed material was illuminated with light from a calibrated 3M™ ESPE™ Freelight™ 2 Dental Curing Light for 20 sec, resulting in a hard, polymerized material. These pastes are suitable for use as a component of a dental liner/base.
The handling of this paste was examined using a mixing stick and a dental fiber tip applicator. This paste exhibited the same handling properties as Clinpro sealant. A portion of the paste was illuminated with light from a calibrated 3M™ ESPE™ Freelight™ 2 Dental Curing Light for 20 sec, resulting in a hard, polymerized material. These compositions are suitable for use as a dental sealant.
The composition was painted onto a frosted glass slide in a thin layer using the brush provided with the Vanish varnish product. This paste exhibited the same creamy, easy-to-spread handling properties as Vanish varnish. After approximately 10 min in air the layer dried to form a soft film, the same as that formed by Vanish varnish under similar conditions. This composition is suitable for use as a dental varnish.
This application is a national stage filing under 35 U.S.C. 371 of PCT/US2009/063943, filed Nov. 11, 2009, which claims priority to U.S. Provisional Patent Application No. 61/121,702, filed Dec. 11, 2008, the disclosures of which are incorporated by reference in their entirety herein.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2009/063943 | 11/11/2009 | WO | 00 | 4/14/2011 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2010/068359 | 6/17/2010 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2323550 | Lukens | Jul 1943 | A |
| 3018262 | Schroeder | Jan 1962 | A |
| 3117099 | Proops | Jan 1964 | A |
| 3442849 | Tashlick | May 1969 | A |
| 3786116 | Milkovich | Jan 1974 | A |
| 3804794 | Schmitt | Apr 1974 | A |
| 3842059 | Milkovich | Oct 1974 | A |
| 3926870 | Keegan | Dec 1975 | A |
| 4043327 | Potter | Aug 1977 | A |
| 4083955 | Grabenstetter | Apr 1978 | A |
| 4110083 | Benedict | Aug 1978 | A |
| 4141864 | Rijke | Feb 1979 | A |
| 4157387 | Benedict | Jun 1979 | A |
| 4198394 | Faunce | Apr 1980 | A |
| 4209434 | Wilson | Jun 1980 | A |
| 4259075 | Yamauchi | Mar 1981 | A |
| 4298738 | Lechtken | Nov 1981 | A |
| 4324744 | Lechtken | Apr 1982 | A |
| 4356296 | Griffith | Oct 1982 | A |
| 4385109 | Lechtken | May 1983 | A |
| 4396378 | Orlowski | Aug 1983 | A |
| 4397837 | Raaf | Aug 1983 | A |
| 4418057 | Groat | Nov 1983 | A |
| 4499251 | Omura | Feb 1985 | A |
| 4503169 | Randklev | Mar 1985 | A |
| 4518430 | Brown | May 1985 | A |
| 4533544 | Groat | Aug 1985 | A |
| 4537940 | Omura | Aug 1985 | A |
| 4539382 | Omura | Sep 1985 | A |
| 4612053 | Brown | Sep 1986 | A |
| 4642126 | Zador | Feb 1987 | A |
| 4648843 | Mitra | Mar 1987 | A |
| 4652274 | Boettcher | Mar 1987 | A |
| 4665217 | Reiners | May 1987 | A |
| 4684673 | Adachi | Aug 1987 | A |
| 4695251 | Randklev | Sep 1987 | A |
| 4698318 | Vogel | Oct 1987 | A |
| 4708652 | Fujiu et al. | Nov 1987 | A |
| 4710523 | Lechtken | Dec 1987 | A |
| 4737593 | Ellrich | Apr 1988 | A |
| 4752338 | Reiners et al. | Jun 1988 | A |
| 4820506 | Kleinberg et al. | Apr 1989 | A |
| 4871786 | Aasen | Oct 1989 | A |
| 4872936 | Engelbrecht | Oct 1989 | A |
| 4880660 | Aasen | Nov 1989 | A |
| 4923683 | Sakuma | May 1990 | A |
| 4933173 | Clark | Jun 1990 | A |
| 5015628 | Reynolds | May 1991 | A |
| 5026902 | Fock | Jun 1991 | A |
| 5037639 | Tung | Aug 1991 | A |
| 5055497 | Okada | Oct 1991 | A |
| 5063257 | Akahane | Nov 1991 | A |
| 5071637 | Pellico | Dec 1991 | A |
| 5074916 | Hench | Dec 1991 | A |
| 5076844 | Fock | Dec 1991 | A |
| 5130347 | Mitra | Jul 1992 | A |
| 5135396 | Kuboki | Aug 1992 | A |
| 5154762 | Mitra | Oct 1992 | A |
| 5162267 | Smyth | Nov 1992 | A |
| 5192815 | Okada | Mar 1993 | A |
| 5296026 | Monroe | Mar 1994 | A |
| 5332429 | Mitra | Jul 1994 | A |
| 5340776 | Paschke | Aug 1994 | A |
| 5468477 | Kumar | Nov 1995 | A |
| 5501727 | Wang | Mar 1996 | A |
| 5508342 | Antonucci | Apr 1996 | A |
| 5525648 | Aasen | Jun 1996 | A |
| 5530038 | Yamamoto | Jun 1996 | A |
| 5545676 | Palazzotto | Aug 1996 | A |
| 5571502 | Winston | Nov 1996 | A |
| 5603922 | Winston | Feb 1997 | A |
| 5605675 | Usen | Feb 1997 | A |
| 5607663 | Rozzi | Mar 1997 | A |
| 5614175 | Winston | Mar 1997 | A |
| 5641347 | Grabowski | Jun 1997 | A |
| 5662887 | Rozzi | Sep 1997 | A |
| 5693313 | Shiraishi | Dec 1997 | A |
| 5725882 | Kumar | Mar 1998 | A |
| 5735942 | Litkowski | Apr 1998 | A |
| 5762950 | Yli-Urpo | Jun 1998 | A |
| 5817296 | Winston | Oct 1998 | A |
| 5824289 | Stoltz | Oct 1998 | A |
| 5833957 | Winston | Nov 1998 | A |
| 5856373 | Kaisaki | Jan 1999 | A |
| 5858333 | Winston | Jan 1999 | A |
| 5866102 | Winston | Feb 1999 | A |
| 5866630 | Mitra | Feb 1999 | A |
| 5876208 | Mitra | Mar 1999 | A |
| 5883153 | Roberts | Mar 1999 | A |
| 5888491 | Mitra | Mar 1999 | A |
| 5891233 | Salonen | Apr 1999 | A |
| 5891448 | Chow | Apr 1999 | A |
| 5895641 | Usen | Apr 1999 | A |
| 5910273 | Thiel | Jun 1999 | A |
| 5922786 | Mitra | Jul 1999 | A |
| 5958915 | Abe | Sep 1999 | A |
| 5980697 | Kolb | Nov 1999 | A |
| 5981475 | Reynolds | Nov 1999 | A |
| 5993786 | Chow | Nov 1999 | A |
| 6030606 | Holmes | Feb 2000 | A |
| 6036494 | Cohen | Mar 2000 | A |
| 6036762 | Sambasivan | Mar 2000 | A |
| 6036944 | Winston | Mar 2000 | A |
| 6056930 | Tung | May 2000 | A |
| 6063832 | Yuhda | May 2000 | A |
| 6086374 | Litkowski | Jul 2000 | A |
| 6136737 | Todo | Oct 2000 | A |
| 6136885 | Rusin | Oct 2000 | A |
| 6159449 | Winston | Dec 2000 | A |
| 6180688 | Rheinberger | Jan 2001 | B1 |
| 6187833 | Oxman | Feb 2001 | B1 |
| 6200553 | Busch, Jr. | Mar 2001 | B1 |
| 6244871 | Litkowski | Jun 2001 | B1 |
| 6251963 | Köhler | Jun 2001 | B1 |
| 6270562 | Jia | Aug 2001 | B1 |
| 6297181 | Kunert | Oct 2001 | B1 |
| 6303104 | Winston | Oct 2001 | B1 |
| 6306926 | Bretscher | Oct 2001 | B1 |
| 6312668 | Mitra | Nov 2001 | B2 |
| 6312688 | Poustka | Nov 2001 | B1 |
| 6335413 | Zech | Jan 2002 | B1 |
| 6338751 | Litkowski | Jan 2002 | B1 |
| 6353039 | Rheinberger | Mar 2002 | B1 |
| 6355271 | Bell | Mar 2002 | B1 |
| 6355704 | Nakatsuka | Mar 2002 | B1 |
| 6361761 | Joziak | Mar 2002 | B1 |
| 6365134 | Orlowski | Apr 2002 | B1 |
| 6372198 | Abbate | Apr 2002 | B1 |
| 6387981 | Zhang | May 2002 | B1 |
| 6391286 | Mitra | May 2002 | B1 |
| 6398859 | Dickens | Jun 2002 | B1 |
| 6413538 | Garcia | Jul 2002 | B1 |
| 6426114 | Troczynski | Jul 2002 | B1 |
| 6437019 | Rusin | Aug 2002 | B1 |
| 6451290 | Winston | Sep 2002 | B2 |
| 6458868 | Okada | Oct 2002 | B1 |
| 6461632 | Gogolewski | Oct 2002 | B1 |
| 6521264 | Lacout | Feb 2003 | B1 |
| 6566413 | Weinmann | May 2003 | B1 |
| 6572693 | Wu | Jun 2003 | B1 |
| 6596061 | Rentschler | Jul 2003 | B1 |
| 6596403 | Mitra | Jul 2003 | B2 |
| 6613812 | Bui | Sep 2003 | B2 |
| 6624236 | Bissinger | Sep 2003 | B1 |
| 6632412 | Peltola | Oct 2003 | B2 |
| 6649669 | Dickens | Nov 2003 | B2 |
| 6652875 | Bannister | Nov 2003 | B1 |
| 6653365 | Jia | Nov 2003 | B2 |
| 6709744 | Day | Mar 2004 | B1 |
| 6730156 | Windisch | May 2004 | B1 |
| 6733818 | Luo | May 2004 | B2 |
| 6750268 | Hino | Jun 2004 | B2 |
| 6765036 | Dede | Jul 2004 | B2 |
| 6770265 | Ishihara | Aug 2004 | B2 |
| 6770325 | Troczynski | Aug 2004 | B2 |
| 6780844 | Reynolds | Aug 2004 | B1 |
| 6790877 | Nakatsuka | Sep 2004 | B2 |
| 6793725 | Chow | Sep 2004 | B2 |
| 6818682 | Falsafi | Nov 2004 | B2 |
| 6852795 | Bissinger et al. | Feb 2005 | B2 |
| 6852822 | Bissigner et al. | Feb 2005 | B1 |
| 6887920 | Ohtsuki | May 2005 | B2 |
| 6923989 | Lacout | Aug 2005 | B2 |
| 6960079 | Brennan | Nov 2005 | B2 |
| 6982288 | Mitra | Jan 2006 | B2 |
| 7030049 | Rusin | Apr 2006 | B2 |
| 7090720 | Kessler | Aug 2006 | B2 |
| 7090721 | Craig | Aug 2006 | B2 |
| 7156911 | Kangas | Jan 2007 | B2 |
| 7173074 | Mitra | Feb 2007 | B2 |
| 7250452 | Falsafi | Jul 2007 | B2 |
| 7255562 | Rusin | Aug 2007 | B2 |
| 7335691 | Orlowski | Feb 2008 | B2 |
| 7344749 | Becker | Mar 2008 | B2 |
| 7361216 | Kangas | Apr 2008 | B2 |
| 20020090525 | Rusin | Jul 2002 | A1 |
| 20030018098 | Falsafi | Jan 2003 | A1 |
| 20030082232 | Lee | May 2003 | A1 |
| 20030149129 | Dickens | Aug 2003 | A1 |
| 20030157357 | Rusin | Aug 2003 | A1 |
| 20030158302 | Chaput | Aug 2003 | A1 |
| 20030166737 | Dede | Sep 2003 | A1 |
| 20030166740 | Mitra | Sep 2003 | A1 |
| 20030167967 | Narhi | Sep 2003 | A1 |
| 20030181541 | Wu | Sep 2003 | A1 |
| 20030195273 | Mitra | Oct 2003 | A1 |
| 20030198914 | Brennan | Oct 2003 | A1 |
| 20040010055 | Bui | Jan 2004 | A1 |
| 20040052860 | Reid | Mar 2004 | A1 |
| 20040065228 | Kessler | Apr 2004 | A1 |
| 20040146466 | Baig | Jul 2004 | A1 |
| 20040185013 | Burgio | Sep 2004 | A1 |
| 20040206932 | Abuelyaman | Oct 2004 | A1 |
| 20040241238 | Sepulveda | Dec 2004 | A1 |
| 20050175965 | Craig | Aug 2005 | A1 |
| 20050175966 | Falsafi | Aug 2005 | A1 |
| 20050176844 | Aasen | Aug 2005 | A1 |
| 20050196353 | Sugiyama | Sep 2005 | A1 |
| 20050201987 | Pirhonen | Sep 2005 | A1 |
| 20050252413 | Kangas | Nov 2005 | A1 |
| 20050256223 | Kolb | Nov 2005 | A1 |
| 20060034975 | Schechner | Feb 2006 | A1 |
| 20060286044 | Robinson | Dec 2006 | A1 |
| 20070105975 | Orlowski | May 2007 | A1 |
| 20070178220 | Karlinsey | Aug 2007 | A1 |
| 20070253919 | Boyd | Nov 2007 | A1 |
| 20080187500 | Karlinsey | Aug 2008 | A1 |
| 20080299520 | Ali | Dec 2008 | A1 |
| 20080305457 | Ali | Dec 2008 | A1 |
| 20100260849 | Rusin | Oct 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2098039 | Dec 1994 | CA |
| 0 173 567 | Mar 1986 | EP |
| 0 201 031 | Nov 1986 | EP |
| 0 201 778 | Nov 1986 | EP |
| 0298501 | Jul 1988 | EP |
| 0 344 832 | Dec 1989 | EP |
| 0 373 384 | Jun 1990 | EP |
| 0 405 682 | Jan 1991 | EP |
| 0 529 212 | Mar 1993 | EP |
| 0 634 373 | Jan 1995 | EP |
| 0 712 622 | May 1996 | EP |
| 1 051 961 | Nov 2000 | EP |
| 1 285 646 | Feb 2003 | EP |
| 1 434 081 | Apr 1976 | GB |
| 1 560 992 | Feb 1980 | GB |
| 04-198112 | Jul 1992 | JP |
| 4-329960 | Nov 1992 | JP |
| 06-199622 | Jul 1994 | JP |
| 6-311954 | Nov 1994 | JP |
| 6-321515 | Nov 1994 | JP |
| 10 167942 | Jun 1998 | JP |
| 1 792 695 | Feb 1993 | SU |
| WO 8707615 | Dec 1987 | WO |
| WO 9312760 | Jul 1993 | WO |
| WO 9402411 | Feb 1994 | WO |
| WO 9522956 | Aug 1995 | WO |
| WO 9736943 | Oct 1997 | WO |
| WO 9817236 | Apr 1998 | WO |
| WO 9907326 | Feb 1999 | WO |
| WO 9934772 | Jul 1999 | WO |
| WO 0006108 | Feb 2000 | WO |
| WO 0037033 | Jun 2000 | WO |
| WO 0038619 | Jul 2000 | WO |
| WO 0040206 | Jul 2000 | WO |
| WO 0042092 | Jul 2000 | WO |
| WO 0107444 | Feb 2001 | WO |
| WO 0130305 | May 2001 | WO |
| WO 0130306 | May 2001 | WO |
| WO 0130307 | May 2001 | WO |
| WO 0141822 | Jun 2001 | WO |
| WO 0192271 | Dec 2001 | WO |
| WO 0249578 | Jun 2002 | WO |
| WO 02072038 | Sep 2002 | WO |
| WO 02085313 | Oct 2002 | WO |
| WO 02094204 | Nov 2002 | WO |
| WO 03052164 | Jun 2003 | WO |
| WO 03063804 | Aug 2003 | WO |
| WO 03074009 | Sep 2003 | WO |
| WO 03095085 | Nov 2003 | WO |
| WO 2004000252 | Dec 2003 | WO |
| WO 2004035029 | Apr 2004 | WO |
| WO 2004035077 | Apr 2004 | WO |
| WO 2004060327 | Jul 2004 | WO |
| WO 2004075862 | Sep 2004 | WO |
| WO 2005018581 | Mar 2005 | WO |
| WO 2006020760 | Feb 2006 | WO |
| WO 2006055317 | May 2006 | WO |
| WO 2006055327 | May 2006 | WO |
| WO 2006055328 | May 2006 | WO |
| WO 2006055329 | May 2006 | WO |
| WO 2009076491 | Jun 2009 | WO |
| Entry |
|---|
| Aikawa,“Scale-up Studies on High Shear Wet Granulation Process from Mini-Scale to Commercial Scale”, Chem. Pharm. Bull., Oct. 2008, vol. 56, No. 10, pp. 1431-1435, (XP002575423). |
| Ana, “Effects of added bioactive glass on the stting and mechanical properties of resin-modified glass ionomer cement”, Biomaterials, Aug. 2003, vol. 24, No. 18, pp. 3061-3067, (ISSN: 0142-9612). |
| ANSI/ADA Spec. No. 27 “Resin-Based Filling Materials,” pp. 1-27 (1993). |
| ASTM D 2805-95, “Standard Test Method for Hiding Power of Paints by Reflectometry,” 1995, pp. 307-312. |
| CAO, “Bioactive Materials”, Ceramics International, 1996, vol. 22, No. 6, pp. 493-507. |
| D'Andrea, “Covalent surface modification of calcium hydroxyapatite using n-alkyl and n-fluoroalkylphosphonic acids” Langmuir, 2003, vol. 19, No. 19, pp. 7904-7910. |
| Data Sheet: Comparison of Recaldent (PP-ACP) Technology, GC America Inc., Dec. 2006, 1 pg. |
| Dumas, “Structure primaire de la caseine β bovine,” Eur. J. Biochem., 1972, vol. 25, pp. 505-514. |
| Hench, “Bioactive Glasses, Chapter 3”, An Introduction to Bioceramics, Advanced Series in Ceramics—vol. 1, 1993, pp. 41-61. |
| Höland, “Machineable and Phosphate Glass-Ceramics, Chapter 8”, An Introduction to Bioceramics, Advanced Series in Ceramics—vol. 1, 1993, 125-136. |
| Kawakami,“Silicone Macromers for Graft Polymer Synthesis,” Polymer Journal, Jan. 1982, vol. 14, No. 11, pp. 913-917. |
| Kawakami, “Synthesis and Copolymerization of Polysiloxane Macromers,” ACS Polymer Preprints, 1984, vol. 25, No. 1, pp. 245-246. |
| Kawakami, “Synthesis and Silicone Graft Polymers and a Study of Their Surface Active Properties,” Makromol. Chem., 1984, vol. 185, pp. 9-18. |
| Kokubo, “A/W Glass Ceramic: Processing and Properties, Chapter 5”, An Introduction to Bioceramics, Advanced Series in Ceramics—vol. 1, 1993, pp. 75-88. |
| Lee, Handbook of Epoxy Resins, 1967, 3 pages. |
| Leigh, IUPAC, Nomenclature of Inorganic Chemistry, Recommendations 1990 (1990), pp. 1-289. |
| Makinen, “Solubility of Calcium Salts, Enamel, and Hydroxyapatite in Aqueous Solutions of Simple Carbohydrates”, Calcif. Tissue Int., Jan. 1984, vol. 36, No. 1, pp. 64-71, (XP009131443). |
| Mazzaoui, “Incorporation of Casein Phosphopeptide-Amorphous Calcium Phosphate into a Glass-ionomer Cement”, Journal of Dental Research, Nov. 2003, vol. 82, No. 11, pp. 914-918. |
| McKenzie, Advances in Protein Chemistry, vol. 22, 1967, pp. 75-135. |
| NSI Dental Pty Ltd., Topacal, C-5 Product Information and Supporting Publications, Better Teeth for Everyone, May 2003, 32 pages. |
| Product data sheet (i.e. sales or company literature): “AMCO—Casehesive Protein Polymers”, American Casein Company, Oct. 3, 2001, 1 pg. |
| Product data sheet (i.e. sales or company literature): “AMCO—Edible Powdered Protein Products (page 2)” American Casein Company, Sep. 6, 2004 [retrieved from internet on Feb. 9, 2005], <URL: http://www.americancase.com/edible—2.htm>; 1 page. |
| Product data sheet (i.e. sales or company literature): “AMCO—Protein Polymers for Technical Applications”, American Casein Company, Sep. 6, 2004 [retrieved from the internet on Feb. 9, 2005], <URL: http://www.americacom/technical.htm>; 1 pg. |
| Product data sheet (i.e. sales or company literature): “American Casein Company—AMCO”, American Casein Company, Sep. 6, 2004 [retrieved from internet on Feb. 9, 2005], <URL:http://www.americancasein.com>; 2pgs. |
| Product data sheet (i.e. sales or company literature): “Bone-replacement individually designed—3di Ltd.” 3di Ltd., Advantages of Biovert II, [retrieved on internet from Feb. 9, 2005], <URL: http://www.3di.de/—englisch/materialspezifika/material/htm>; 1 pg. |
| Product data sheet (i.e. sales or company literature): “Bone-replacement individually designed—3di Ltd.” 3di Ltd., Physical parameters, [retrieved on internet from Feb. 9, 2005], <URL: http://www.3di.de/—englisch/materialspezifika/bioverit/htm>; 1 pg. |
| Product data sheet (i.e. sales or company literature): “Cerabone A-W Artificial Vertebrae, Intervertebral Spacer, Spinous Process Spacer,” received Jun. 9, 1998, 8 pages. |
| Product data sheet (i.e. sales or company literature): “Cerabone A-W Cerabone A-W Iliac Spacer”, received Jun. 9, 1998, 8 pages. |
| Product data sheet (i.e. sales or company literature): “Corporate Chronology Nippon Electric Glass 50 Years and Beyond” Nippon Electric Glass Co., Ltd., Otsu, Shiga, Japan, [online], Aug. 1, 1998, [retrieved on Feb. 9, 2005], URL <http://www.neg.co.jp/eng/company/history.html>; 4 pgs. |
| Product data sheet (i.e. sales or company literature): “NSI Dental—Manufactureer of dental restoratives for the dental practitioner”, NSI Dental Pty Limited, [retrieved on Feb. 9, 2005], URL<http://www.nsidental.com/>; 5 pgs. |
| Product data sheet (i.e. sales or company literature): “Revitalize Teeth! NovaMin Tooth Remineralization for Oral Care Products”, NovaMin Technology Inc, Alachua, FL, [retrieved on Feb. 9, 2005], URL<http://www.novamin.com/>; 1 page. |
| Product data sheet (i.e. sales or company literature): “Welcome to Recaldent”, Recaldent Pty Ltd, University of Melbourne, Australia, [retrieved on Feb. 9, 2005], URL <http://www.recaldent.com/index.htm>; 1 pg. |
| Recaldent, Product Advertisement, Journal of Dental Research, Jan. 2005, vol. 84, No. 1, 2 pages. |
| Reynolds, “Retention in Plaque and Remineralization of Enamel Lesions by Various Forms of Calcium in a Mouthrinse or Sugar-free Chewing Gum”, Journal of Dental Research, Mar. 2003, vol. 82, No. 3, pp. 206-211. |
| Shen, “Remineralization of Enamel Subsurface Lesions by Sugar-free Chewing Gum Containing Casein Phosphopeptide-Amorphous Calcium Phosphate” Journal of Dental Research, Dec. 2001, vol. 80, No. 12, pp. 2066-2070. |
| Shimabayashi, “Formation of Hydroxyapatite in the Presence of Phosphorylated and Sulfated Polymer in an Aqueous Phase”, Mineral Scale Formation and Inhibition, 1995, pp. 157-168. |
| Skrtic, “Amorphous Calcium Phosphate-Based Bioactive Polymeric Composites for Mineralized Tissue Regeneration,” Journal of Research of the National Institute of Standards and Technology, May-Jun. 2003, vol. 108, No. 3, pp. 167-182. |
| Tanaka, “Surface modification of calcium hydroxyapatite with hexyl and decyl phosphates” Colloids and Surfaces A: Physicochemical and Engineering Aspects, May 1997, vol. 125, No. 1, pp. 53-62. |
| Tanaka, “Surface structure and properties of calcium hydroxyapatite modified by Hexamethyldisilazane”, Journal of Colloid and Interface Science, Oct. 1998, vol. 206, No. 1, pp. 205-211. |
| Tantbirojin, “Surface Modulation of Dental Hard Tissues,” Ph.D. Thesis, University of Minnesota, Dec. 1998, pp. 1-217. |
| The Merck Index, An Encyclopedia of Chemical, Drugs, and Biologicals, Twelfth Edition, 1996, pp. 309-310. |
| Weast, CRC Handbook of Chemistry and Physics, 51st Edition, 1970, p. B-77. |
| Xu, “Nanocomposites with Ca and PO4release: Effects of reinforcement, dicalcium phosphate particle size and silanization”. Dental Materials, Mar. 2007, vol. 23 No. 12, pp. 1482-1491. |
| Yamamuro, “A/W Glass Ceramics: Clinical Applications,” Introduction to Bioceramics, 89-103, (1993). |
| Yli-Urpo, “Release of Silica, Calcium, Phosphorus, and Fluoride from Glass lonomer Cement Containing Bioactive Glass” Journal of Biomaterials Applications, Jul. 2004, vol. 19, No. 1, pp. 5-20. |
| International Search Report for PCT/US2009/063943, mailed Apr. 29, 2010, 5 pages. |
| International Preliminary Report on Patentability and Written Opinion for PCT/US2009/063943 dated Jun. 14, 2011; 11 pgs. |
| Number | Date | Country | |
|---|---|---|---|
| 20110229421 A1 | Sep 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61121702 | Dec 2008 | US |
